Group 1 - The company conducted a telephone survey with institutional investors on January 22, 2026, discussing key issues such as drug development, subsidiary operations, health product channels, and dividend policies [1] - The company is making steady progress in clinical research for key drug products, including studies on diabetes foot, bone pain, and other areas, which will lay the foundation for expanding application scenarios [2] - The company plans to continue promoting existing product development while selectively extending external projects to complete its product matrix [2] Group 2 - The provincial pharmaceutical company will implement a "double rise and double drop" strategy, focusing on stabilizing existing hospital and distribution market shares while expanding non-drug businesses and new specialty pharmacies to cultivate new growth points [3] - The company aims to enhance operational efficiency by optimizing supply chain management and improving accounts receivable and inventory structures [3] Group 3 - In the health product sector, the company achieved significant breakthroughs in online channels in 2025, with a notable increase in product awareness and sales through strategic partnerships with e-commerce platforms [4] - The company’s toothpaste maintained the top market share in the domestic channel in the first half of 2025, and its anti-hair loss shampoo ranked first on Tmall during the "618" shopping festival [4] Group 4 - The company announced a high dividend policy for 2024, with a total cash dividend of approximately 4.279 billion yuan, representing 90.09% of the net profit attributable to shareholders [5] - For the first half of 2025, the company plans to distribute a cash dividend of 1.818 billion yuan, which is 50.05% of the net profit for that period [5] Group 5 - The strategic layout of the company in drug research, subsidiary operations, channel expansion, and shareholder returns is becoming clearer, with ongoing product development and supply chain optimization expected to strengthen its industry position [6] - The high dividend policy reflects the company's commitment to long-term returns for investors [6]

Group 1 - The core strategy of Yunnan Baiyao's pharmaceutical business group focuses on becoming the leading brand in the field of pain management, with significant growth in aerosol and plaster products driven by a comprehensive marketing approach [2] - The O2O sales channel has seen a year-on-year increase of over 20%, with e-commerce GMV reaching 254 million yuan, supported by effective online content marketing [2] - The health products segment has maintained its leading market share in toothpaste and achieved top rankings in anti-hair loss shampoo on major e-commerce platforms [4] Group 2 - The nuclear medicine research and development is progressing steadily, with the INR101 diagnostic project entering phase III clinical trials and INR102 treatment project starting phase I trials [3] - Yunnan Baiyao is pursuing a dual-driven development strategy, focusing on both internal optimization and external mergers and acquisitions to enhance its industry portfolio [5]

Group 1: Product Development and Clinical Research - The pharmaceutical division is focusing on the secondary development of key products, including clinical studies on Yunnan Baiyao (powder and capsules) for diabetic foot and bone pain, and Gongxue Ning capsules for treating abnormal uterine bleeding [2][3] - Recent clinical research results show Gongxue Ning capsules effectively reduce post-abortion vaginal bleeding and complications, with good overall safety [3] - The Qi Xue Kang oral solution is undergoing multi-center clinical studies for hypertension, with the first patient enrolled successfully [3] Group 2: Business Strategy and Market Expansion - The provincial pharmaceutical company aims to enhance market share in existing hospitals and distribution channels through a "double rise and double drop" strategy, focusing on non-drug businesses and new specialty pharmacies [4] - Efforts will be made to optimize supply chain management and improve accounts receivable and inventory structure, aiming for a patient-centered healthcare ecosystem [4] Group 3: Online Sales Performance - The pharmaceutical division's O2O sales increased by over 20% in the first half of 2025, with significant online marketing efforts boosting product awareness and sales [6] - During the 2025 "618" shopping festival, Yunnan Baiyao toothpaste ranked first in the domestic market share across all channels [6] Group 4: Dividend Distribution - For the 2024 fiscal year, the company plans to distribute a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.16 billion CNY, which represents 90.09% of the net profit attributable to shareholders [7][8] - In the first half of 2025, a cash dividend of 10.19 CNY per 10 shares will be distributed, amounting to 1.82 billion CNY, with special dividends accounting for 50.05% of the net profit for that period [8]

Core Insights - The Shanghai Municipal Medical Procurement Management Office has released a list of drug varieties for public bidding and procurement supervision for September 2025, highlighting products that exceed the "yellow line" threshold, did not pass fairness assessments, or are under close monitoring [1][10] Group 1: Drug Varieties - The list includes exclusive products such as Ma Ren Run Chang Soft Capsules, Yunnan Baiyao Aerosol, and Bu Xin Qi Oral Liquid [1] - New applications exceeding the "yellow line" include exclusive products from Beijing Tongrentang and Yunnan Baiyao Group [1] - Existing products on the "yellow line" list include exclusive items like Regaglinide Metformin Tablets (II) from Zhejiang Tailisen Pharmaceutical [1] Group 2: Regulatory Framework - Since September 2018, Shanghai has implemented a public bidding mechanism for drug procurement, utilizing a pricing inquiry model based on "information push, green line reference, yellow line reminder, and red line interception" [9] - Starting from June 2024, the list will also include products that did not pass fairness assessments and those under close monitoring [9] Group 3: Procurement Guidelines - The Shanghai Municipal Medical Procurement Management Office emphasizes that the published list serves as a reminder for medical institutions to price reasonably based on market supply and demand, ensuring clinical needs are met while avoiding unreasonable price adjustments [10]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of CNY 4.751 billion, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year growth of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] Group 2: Online Sales and Marketing - The pharmaceutical business group expanded its online market, with O2O sales increasing by over 20% year-on-year [3] - During the 2025 "618" shopping festival, the company’s main products ranked significantly higher on the regular medicine list [3] - E-commerce platforms attracted 48.45 million visitors, resulting in 3.54 million consumers and generating a GMV of CNY 254 million [3] Group 3: Health Products Strategy - The health products group aims to become a leader in high-quality health lifestyle products, focusing on oral care and hair care [4] - Continuous enhancement of oral product advantages and rapid scaling of hair care business are key objectives for the second half of the year [4] Group 4: Nuclear Medicine Development - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [5] - The INR102 therapeutic nuclear medicine project has received clinical trial approval, with 12 patients enrolled in Phase I trials [5] Group 5: Traditional Chinese Medicine Resource Development - The Chinese medicine resource group focuses on Yunnan's local medicinal materials, achieving significant results through collaborative efforts [6] - The establishment of 14 seed source bases and the completion of 90% of the annual target for quality seed promotion [6] - The digital cloud medicine platform achieved a transaction volume exceeding CNY 1 billion, with 18,000 registered farmers [6] Group 6: Future Directions for Provincial Pharmaceutical Company - The provincial pharmaceutical company plans to enhance market share in existing hospitals and distribution channels while exploring new growth areas [8] - Strategies include optimizing supply chain management and improving accounts receivable and inventory structure [8]

Group 1: Health Products Business Performance - In the first half of 2025, the health products segment achieved revenue of 3.442 billion CNY, a year-on-year growth of 9.46% [2] - The segment focuses on a full-channel operation strategy, enhancing offline distribution and increasing online promotion efforts [2] - Key products include oral care toothpaste, which maintains a leading position, and hair care brand Yangyuanqing, which continues to grow driven by online sales [2][4] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment reported a main business revenue of 4.751 billion CNY in the first half of 2025, with a year-on-year increase of 10.8% [5] - Sales of Yunnan Baiyao aerosol exceeded 1.453 billion CNY, showing a significant growth of over 20.9% [5] - Other traditional Chinese medicine products also saw notable growth, with sales of Qianling Jianpi Granules surpassing 100 million CNY and Pudilan Anti-inflammatory Tablets nearing 100 million CNY [5] Group 3: Traditional Chinese Medicine Resource Business - The traditional Chinese medicine resource segment generated external revenue of 914 million CNY in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [6] - The segment implements a "six unifications" operational model to enhance the traditional Chinese medicine industry chain [7] Group 4: R&D and Innovation Progress - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative drugs [8] - In the first half of 2025, the company initiated phase III clinical trials for the prostate cancer diagnostic nuclear drug project INR101, with 60 subjects enrolled [9] - The innovative drug project INR102 for prostate cancer treatment received clinical trial approval, and phase I trials have commenced [9] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [10] - The total cash dividend for 2024, including special dividends, amounted to 4.279 billion CNY, representing 90.09% of the net profit attributable to shareholders [10] - In the first half of 2025, the company distributed a cash dividend of 10.19 CNY per 10 shares, totaling 1.818 billion CNY, which accounted for 50.05% of the net profit for that period [10]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of 4.751 billion yuan, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded 1.453 billion yuan, with a significant year-on-year growth of over 20.9% [2] - Other core products, including Yunnan Baiyao plaster and capsules, also saw notable growth, contributing to the overall revenue increase [2] - Plant-based products, such as Qixue Kang oral liquid, reached sales of 202 million yuan, with a year-on-year growth of approximately 116.2% [2] Group 2: Health Product Channel Development - The company has established a comprehensive national sales team for health products, maintaining a leading market share in Yunnan Baiyao toothpaste [4] - Continuous optimization of the entire channel has strengthened traditional offline advantages while also focusing on emerging retail formats like instant retail and community group buying [4] Group 3: Traditional Chinese Medicine Cultivation Achievements - The company has implemented a precise research and transformation model for seed innovation, achieving coverage of ten major Yunnan medicinal sources [5] - The area of high-quality seed promotion has reached 90% of the annual target, with significant progress in the construction of "Yun Medicine Seed Valley" [5] - Over 7,000 acres of GAP management have been added for various medicinal herbs, integrating low-altitude economy and IoT technology [5] Group 4: Online Sales Performance - The pharmaceutical business group has expanded its online market, with O2O sales increasing by over 20% year-on-year [6] - During the 2025 "618" shopping festival, the company achieved a GMV of 254 million yuan through e-commerce platforms, attracting 48.45 million visitors [7] - Yunnan Baiyao toothpaste maintained the top market share in the domestic channel, while Yangyuan Qing ranked first in Tmall for anti-hair loss shampoo [7] Group 5: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [8] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled [8]

Core Insights - Health consumption is evolving from an optional demand to a basic necessity in daily life, driven by proactive health investment rather than reactive measures to illness [1] - The aging population and increased health risk awareness among younger generations are key factors influencing this shift [1] - E-commerce platforms, particularly JD Health, are becoming the primary channels for health product distribution, reflecting changes in consumer behavior and preferences [1] Trend 1: Reshaping Dietary Structure - Health products are transitioning from being age-specific to essential for all age groups, emphasizing daily necessity over reactive supplementation [2] - The "Healthy China 2030" strategy is driving a wave of health consumption focused on nutrition, with a significant portion of health product buyers being young parents [3] Trend 2: Rational Consumption and Trust - Consumers are increasingly focused on product ingredients and efficacy, seeking targeted solutions for sub-health issues like obesity and sleep disorders [6] - The sales of sleep aid products have surged, particularly among younger consumers, indicating a shift towards evidence-based health solutions [7] Trend 3: Home Health Management - The demand for professional medical devices and home care services is rising, driven by an aging population and chronic disease management needs [8] - JD Health reports significant growth in home health monitoring devices, reflecting the increasing importance of user-friendly and effective health management tools [9] Trend 4: Emotional and Experiential Health Needs - There is a growing trend for health products to not only provide health benefits but also enhance sensory experiences and emotional well-being [12] - The market for health-related products is diversifying, with an increase in female consumers in traditionally male-dominated categories, indicating a shift in societal perceptions of health and wellness [14]

Core Insights - Yunnan Baiyao has transformed from a traditional Chinese medicine brand into a modern pharmaceutical group, achieving significant growth in revenue and net profit over the past 32 years since its listing [2] - The company emphasizes strategic focus and product quality as keys to success in a changing external environment [2] Financial Performance - Revenue increased from 0.58 billion to 40.033 billion, a growth of 690 times; net profit rose from 0.13 billion to 4.749 billion, a growth of 365 times [2] - In the first three quarters of 2025, Yunnan Baiyao achieved revenue of 30.654 billion, a year-on-year increase of 2.47%, and net profit of 4.777 billion, a year-on-year increase of 10.41% [4] Digital Transformation - The company has implemented a comprehensive digital transformation across its entire supply chain, establishing a "Smart Cloud Medicine" platform to enhance quality control and traceability of traditional Chinese medicinal materials [4][6] - The smart factory has reduced production process switching time from 20 minutes to 1 minute and active ingredient testing time from 710 minutes to 2 minutes [3] Industry Challenges - The traditional Chinese medicine industry faces challenges such as unstable quality and price volatility due to the agricultural nature of medicinal materials [3] - Yunnan Baiyao is addressing these issues by controlling quality from the seed level and ensuring traceability throughout the production process [5][6] Strategic Focus - The company is focusing on its core business of traditional medicine while also innovating in the pharmaceutical sector, aiming to create a competitive edge through continuous R&D investment [8] - Yunnan Baiyao's strategic planning includes three development curves: short-term focus on major traditional medicine products, mid-term innovation in traditional medicine and new transdermal preparations, and long-term development of nuclear medicine [9] Market Position - In the first half of 2025, the sales revenue from pharmaceuticals and health products reached 8.504 billion, accounting for 40.01% of total revenue, marking an 11.13% year-on-year increase [9]

Group 1 - Dongyangguang Pharmaceutical's total revenue from 2022 to 2024 is projected to reach 14.2 billion, with R&D investment of 2.5 billion over the past three years, and operating profit exceeding 2.1 billion in the last two years [21] - Huaren Sanjiu's R&D investment is expected to reach 950 million in 2024, a 63.97% increase from 2020, with R&D personnel increasing to 876, more than double that of 2020 [21] - Yunnan Baiyao achieved a net profit of 4.777 billion in the first three quarters of 2025, a year-on-year increase of 10.41%, surpassing the full-year profit of 4.749 billion in 2024, marking a historical high for the same period [21] Group 2 - Yunnan Baiyao emphasizes the importance of returning to its core business and focusing on continuous effective R&D investment to build a competitive moat [22] - Huaren Sanjiu is accelerating its merger and integration pace, focusing on consumer health, medical health, and elderly health sectors, while enhancing R&D investment to drive innovation transformation [22] - Dongyangguang Pharmaceutical has developed three self-researched new drugs and has nearly 50 new drugs in the pipeline, actively seeking international markets for growth [26][31] Group 3 - Yanhuilong has invested over 1 billion in R&D from 2021 to 2024, with annual R&D investment accounting for over 20% of its main business revenue [21][51] - The company is shifting from rapid market capture to deep innovation, focusing on high-quality development and establishing a unique project advantage in the IVD industry [49][50] - Yanhuilong's overseas revenue exceeded 200 million in the first three quarters, a nearly 40% year-on-year increase, indicating successful market expansion [54] Group 4 - Yunnan Baiyao's revenue has grown from 58 million to 40.033 billion over 32 years, a 690-fold increase, with net profit rising from 1.3 million to 4.749 billion, a 365-fold increase [40] - The company has established a digital transformation strategy, creating a full-chain digital system to enhance operational efficiency and product quality [41][42] - Yunnan Baiyao's strategic planning includes three R&D curves focusing on traditional Chinese medicine, innovative drugs, and nuclear medicine [48] Group 5 - Dongyangguang Pharmaceutical has built a comprehensive R&D system and a modern factory with an annual production capacity of 1.8 billion tablets [29] - The company is actively integrating AI into drug discovery processes to enhance efficiency and reduce costs [30] - Huaren Sanjiu's revenue is projected to reach 27.6 billion in 2024, a 102% increase from 2020, with a compound annual growth rate of 23.6% in revenue and 24.5% in profit over the past three years [35]